Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates

Kevin O. Saunders, Sampa Santra, Robert Parks, Nicole L. Yates, Laura L. Sutherland, Richard M. Scearce, Harikrishnan Balachandran, Todd Bradley, Derrick Goodman, Amanda Eaton, Sherry A. Stanfield-Oakley, James Tartaglia, Sanjay Phogat, Giuseppe Pantaleo, Mariano Esteban, Carmen E. Gomez, Beatriz Perdiguero, Bertram Jacobs, Karen Kibler, Bette Korber & 6 others David C. Montefiori, Guido Ferrari, Nathan Vandergrift, Hua Xin Liao, Georgia D. Tomaras, Barton F. Haynes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strategy to eradicate AIDS. A critical question is whether antibodies that do not neutralize primary isolate (tier 2) HIV-1 strains can protect from infection. In this study, we investigated the ability of an attenuated poxvirus vector (NYVAC) prime-envelope gp120 boost to elicit potentially protective antibody responses in a rhesus macaque model of mucosal simian-human immunodeficiency virus (SHIV) infection. NYVAC vector delivery of a group M consensus envelope, trivalent mosaic envelopes, or a natural clade B isolate B.1059 envelope elicited antibodies that mediated neutralization of tier 1 viruses, cellular cytotoxicity, and phagocytosis. None of the macaques made neutralizing antibodies against the tier 2 SHIV SF162P3 used for mucosal challenge. Significant protection from infection was not observed for the three groups of vaccinated macaques compared to unvaccinated macaques, although binding antibody to HIV-1 Env correlated with decreased viremia after challenge. Thus, NYVAC Env prime-gp120 boost vaccination elicited polyfunctional, nonneutralizing antibody responses with minimal protective activity against tier 2 SHIV mucosal challenge.

Original languageEnglish (US)
Article numbere02035-17
JournalJournal of Virology
Volume92
Issue number8
DOIs
StatePublished - Apr 1 2018

Fingerprint

Simian Immunodeficiency Virus
immunosuppression
Macaca
Human immunodeficiency virus 1
Primates
HIV-1
Vaccination
vaccination
immune response
Viruses
viruses
antibodies
Antibody Formation
Antibodies
Poxviridae
Human immunodeficiency virus
Viremia
Virus Diseases
Infection
Neutralizing Antibodies

Keywords

  • HIV
  • HIV vaccine
  • Neutralizing antibodies
  • Simian-human immunodeficiency virus

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates. / Saunders, Kevin O.; Santra, Sampa; Parks, Robert; Yates, Nicole L.; Sutherland, Laura L.; Scearce, Richard M.; Balachandran, Harikrishnan; Bradley, Todd; Goodman, Derrick; Eaton, Amanda; Stanfield-Oakley, Sherry A.; Tartaglia, James; Phogat, Sanjay; Pantaleo, Giuseppe; Esteban, Mariano; Gomez, Carmen E.; Perdiguero, Beatriz; Jacobs, Bertram; Kibler, Karen; Korber, Bette; Montefiori, David C.; Ferrari, Guido; Vandergrift, Nathan; Liao, Hua Xin; Tomaras, Georgia D.; Haynes, Barton F.

In: Journal of Virology, Vol. 92, No. 8, e02035-17, 01.04.2018.

Research output: Contribution to journalArticle

Saunders, KO, Santra, S, Parks, R, Yates, NL, Sutherland, LL, Scearce, RM, Balachandran, H, Bradley, T, Goodman, D, Eaton, A, Stanfield-Oakley, SA, Tartaglia, J, Phogat, S, Pantaleo, G, Esteban, M, Gomez, CE, Perdiguero, B, Jacobs, B, Kibler, K, Korber, B, Montefiori, DC, Ferrari, G, Vandergrift, N, Liao, HX, Tomaras, GD & Haynes, BF 2018, 'Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates', Journal of Virology, vol. 92, no. 8, e02035-17. https://doi.org/10.1128/JVI.02035-17
Saunders, Kevin O. ; Santra, Sampa ; Parks, Robert ; Yates, Nicole L. ; Sutherland, Laura L. ; Scearce, Richard M. ; Balachandran, Harikrishnan ; Bradley, Todd ; Goodman, Derrick ; Eaton, Amanda ; Stanfield-Oakley, Sherry A. ; Tartaglia, James ; Phogat, Sanjay ; Pantaleo, Giuseppe ; Esteban, Mariano ; Gomez, Carmen E. ; Perdiguero, Beatriz ; Jacobs, Bertram ; Kibler, Karen ; Korber, Bette ; Montefiori, David C. ; Ferrari, Guido ; Vandergrift, Nathan ; Liao, Hua Xin ; Tomaras, Georgia D. ; Haynes, Barton F. / Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates. In: Journal of Virology. 2018 ; Vol. 92, No. 8.
@article{feff4f7210e94cfca6a1b3eb5d7e953a,
title = "Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates",
abstract = "A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strategy to eradicate AIDS. A critical question is whether antibodies that do not neutralize primary isolate (tier 2) HIV-1 strains can protect from infection. In this study, we investigated the ability of an attenuated poxvirus vector (NYVAC) prime-envelope gp120 boost to elicit potentially protective antibody responses in a rhesus macaque model of mucosal simian-human immunodeficiency virus (SHIV) infection. NYVAC vector delivery of a group M consensus envelope, trivalent mosaic envelopes, or a natural clade B isolate B.1059 envelope elicited antibodies that mediated neutralization of tier 1 viruses, cellular cytotoxicity, and phagocytosis. None of the macaques made neutralizing antibodies against the tier 2 SHIV SF162P3 used for mucosal challenge. Significant protection from infection was not observed for the three groups of vaccinated macaques compared to unvaccinated macaques, although binding antibody to HIV-1 Env correlated with decreased viremia after challenge. Thus, NYVAC Env prime-gp120 boost vaccination elicited polyfunctional, nonneutralizing antibody responses with minimal protective activity against tier 2 SHIV mucosal challenge.",
keywords = "HIV, HIV vaccine, Neutralizing antibodies, Simian-human immunodeficiency virus",
author = "Saunders, {Kevin O.} and Sampa Santra and Robert Parks and Yates, {Nicole L.} and Sutherland, {Laura L.} and Scearce, {Richard M.} and Harikrishnan Balachandran and Todd Bradley and Derrick Goodman and Amanda Eaton and Stanfield-Oakley, {Sherry A.} and James Tartaglia and Sanjay Phogat and Giuseppe Pantaleo and Mariano Esteban and Gomez, {Carmen E.} and Beatriz Perdiguero and Bertram Jacobs and Karen Kibler and Bette Korber and Montefiori, {David C.} and Guido Ferrari and Nathan Vandergrift and Liao, {Hua Xin} and Tomaras, {Georgia D.} and Haynes, {Barton F.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1128/JVI.02035-17",
language = "English (US)",
volume = "92",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Immunogenicity of NYVAC primeprotein boost human immunodeficiency virus type 1 envelope vaccination and simianhuman immunodeficiency virus challenge of nonhuman primates

AU - Saunders, Kevin O.

AU - Santra, Sampa

AU - Parks, Robert

AU - Yates, Nicole L.

AU - Sutherland, Laura L.

AU - Scearce, Richard M.

AU - Balachandran, Harikrishnan

AU - Bradley, Todd

AU - Goodman, Derrick

AU - Eaton, Amanda

AU - Stanfield-Oakley, Sherry A.

AU - Tartaglia, James

AU - Phogat, Sanjay

AU - Pantaleo, Giuseppe

AU - Esteban, Mariano

AU - Gomez, Carmen E.

AU - Perdiguero, Beatriz

AU - Jacobs, Bertram

AU - Kibler, Karen

AU - Korber, Bette

AU - Montefiori, David C.

AU - Ferrari, Guido

AU - Vandergrift, Nathan

AU - Liao, Hua Xin

AU - Tomaras, Georgia D.

AU - Haynes, Barton F.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strategy to eradicate AIDS. A critical question is whether antibodies that do not neutralize primary isolate (tier 2) HIV-1 strains can protect from infection. In this study, we investigated the ability of an attenuated poxvirus vector (NYVAC) prime-envelope gp120 boost to elicit potentially protective antibody responses in a rhesus macaque model of mucosal simian-human immunodeficiency virus (SHIV) infection. NYVAC vector delivery of a group M consensus envelope, trivalent mosaic envelopes, or a natural clade B isolate B.1059 envelope elicited antibodies that mediated neutralization of tier 1 viruses, cellular cytotoxicity, and phagocytosis. None of the macaques made neutralizing antibodies against the tier 2 SHIV SF162P3 used for mucosal challenge. Significant protection from infection was not observed for the three groups of vaccinated macaques compared to unvaccinated macaques, although binding antibody to HIV-1 Env correlated with decreased viremia after challenge. Thus, NYVAC Env prime-gp120 boost vaccination elicited polyfunctional, nonneutralizing antibody responses with minimal protective activity against tier 2 SHIV mucosal challenge.

AB - A preventive human immunodeficiency virus type 1 (HIV-1) vaccine is an essential part of the strategy to eradicate AIDS. A critical question is whether antibodies that do not neutralize primary isolate (tier 2) HIV-1 strains can protect from infection. In this study, we investigated the ability of an attenuated poxvirus vector (NYVAC) prime-envelope gp120 boost to elicit potentially protective antibody responses in a rhesus macaque model of mucosal simian-human immunodeficiency virus (SHIV) infection. NYVAC vector delivery of a group M consensus envelope, trivalent mosaic envelopes, or a natural clade B isolate B.1059 envelope elicited antibodies that mediated neutralization of tier 1 viruses, cellular cytotoxicity, and phagocytosis. None of the macaques made neutralizing antibodies against the tier 2 SHIV SF162P3 used for mucosal challenge. Significant protection from infection was not observed for the three groups of vaccinated macaques compared to unvaccinated macaques, although binding antibody to HIV-1 Env correlated with decreased viremia after challenge. Thus, NYVAC Env prime-gp120 boost vaccination elicited polyfunctional, nonneutralizing antibody responses with minimal protective activity against tier 2 SHIV mucosal challenge.

KW - HIV

KW - HIV vaccine

KW - Neutralizing antibodies

KW - Simian-human immunodeficiency virus

UR - http://www.scopus.com/inward/record.url?scp=85044641978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044641978&partnerID=8YFLogxK

U2 - 10.1128/JVI.02035-17

DO - 10.1128/JVI.02035-17

M3 - Article

VL - 92

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 8

M1 - e02035-17

ER -